Table 1 Descriptive characteristics of included RA patients with T2D
Clinical characteristics | 40 RA patients with T2D |
|---|---|
Demographics | |
Age, years, mean ± sd | 63.4 ± 9.9 |
Female sex, % | 68.9% |
Smoking habit, % | 41.9% |
BMI, mean ± sd | 28.2 ± 7.5 |
RA features | |
RF and/or ACPA, % | 69.8% |
Radiographic erosions, % | 55.8% |
Extra-articular disease, % | 25.6% |
Disease duration, years, % | 7.1 ± 5.3 |
Disease duration ≥ 5 years, % | 63.8% |
Disease duration ≤ 1 years, % | 12.2% |
DAS28-CRP, mean ± sd | 4.1 ± 1.1 |
SDAI, mean ± sd | 18.0 ± 8.3 |
ESR, mm/h mean ± sd | 30.0 ± 15.0 |
CRP, mg/dl, mean ± sd | 0.5 ± 0.4 |
Tender joints, mean ± sd | 8.0 ± 5.0 |
Swollen joints, mean ± sd | 4.1 ± 2.3 |
Patient Global Assessment, mean ± sd | 5.9 ± 2.2 |
VAS pain, mean ± sd | 6.2 ± 3.6 |
Evaluator Global Assessment, mean ± sd | 5.7 ± 2.5 |
HAQ, mean ± sd | 1.25 ± 1 |
Comorbidity feature | |
T2D, % | 100.0% |
HbA1c %, mean ± sd | 6.5 ± 3.9 |
HOMA2-IR, mean ± sd | 1.8 ± 1.2 |
HOMA2-β, mean ± sd | 72.3 ± 53.5 |
FPG, mg/dL, mean ± sd | 136.4 ± 45.7 |
Total Cholesterol, mg/dL, mean ± sd | 192.3 ± 68.6 |
Triglycerides, mg/dL, mean ± sd | 146.6 ± 25.2 |
High blood pressure, % | 60.5% |
Obesity, % | 27.9% |
Dyslipidaemia, % | 18.6% |
Clinical atherosclerosis, % | 4.2% |
Previous Herpes Zoster, % | 0.0% |
Kidney disease, % | 0.0% |
Liver disease, % | 0.0% |
Therapies | |
GCs, % | 34.9% |
GCs, mg/daily, mean ± sd | 2.1 ± 1.6 |
csDMARD(s), % | 72.5% |
MTX, % | 67.4% |
Oral antidiabetic drugs, % | 88.8% |
Metformin, % | 76.5% |
Insulin, % | 11.2% |